Anti-HMB45 is a marker that reacts with antigens present on immature melanosomes. MART-1, or Melan A, is a melanocyte differentiation antigen in melanocytes of normal skin, retina, nevi, and most melanomas.
References
- Orchard G. Evaluation of melanocytic neoplasms: application of a pan-melanoma antibody cocktail. Br J Biomed Sci. 2002; 59:196-202.
- Gupta D, et al. Vaginal melanoma: a clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol. 2002; 26:1450-7.
- Prasad ML, et al. Expression of melanocytic differentiation markers in malignant melanomas of the oral and sinonasal mucosa. Am J Surg Pathol. 2001; 25:782-7
- Yaziji H, et al. Immunohistochemical markers of melanocytic tumors. In J Surg Pathol. 2003; 11:11-5.
- Shidham VB, et al. Improved immunohistochemical evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma with ‘MCW melanoma cocktail’–a mixture of monoclonal antibodies to MART-1, Melan-A, and tyrosinase. BMC Cancer. 2003; 3:15.
- Perez RP, et al., Expression of melanoma inhibitory activity in melanoma and nonmelanoma tissue specimens. Hum Pathol. 2000; 31:1381-8.
- Hoang MP, et al. Recurrent melanocytic nevus: a histologic and immunohistochemical evaluation. J Cutan Pathol. 2001; 28:400-6.
- Baidsen BL, et al. HMB-45 immunohistochemical staining of sentinel lymph nodes: a specific method for enhancing detection of micrometastases in patients with melanoma. Am J Surg Pathol. 2000; 24:1140-6.
- Vaggelli L, et al Radioisotopic lymphatic mapping of the sentinel node in melanoma: importance of immunohistochemistry. Tumori. 2000; 86:346-8.
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
